Fig. 1
Dose-driven innate response in MIMIC®-PTE. Dose-driven innate response in MIMIC®-PTE immune cell populations to the mRNA vaccine, response that is similar to that of the TLR 7/8 agonist resiquimod (R848, 5 μg/ml). The benchmark influenza vaccine Fluzone (FZ) was also evaluated. a Live (live-dead Aqua negative) cell population, as percentage of all singlet cells. Treatment with R848 and higher mRNA vaccine doses drives decreased cell viability and recovery. b Dose-dependent maturation effect from the mRNA vaccine in APCs, as demonstrated by up-regulation of HLA-DR. c Dose-driven activation of APCs, as demonstrated by up-regulation of CD86. d Activation of B-cells, as demonstrated by up-regulation of CD86. e, f cytokine production in response to TLR7/8 stimulus (R848, 5 μg/ml) and the mRNA vaccine. The mRNA vaccine was dosed at the µg concentration listed per million cells (ex. 5 μg/106 cells). Mean ± SEM are shown for n = 24 subjects examined in MIMIC® modules. Statistical analysis was performed with GraphPad Prism software (version 6.04) using Dunnett’s multiple comparisons test. p value indicators ns, *, and **** refer to “no significant correlation”, p < 0.05, p < 0.0001, respectively